Effect Of Capecitabine Metronome Chemotherapy In Hormone Receptor Positive Advanced Breast Cancer

Objective: To observe and compare the efficacy,adverse reactions and quality of life improvement of capecitabine metronome chemotherapy combined with aromatase inhibitors and aromatase inhibitors in hormone receptor positive/human epidermal growth factor receptor 2 negative advanced breast cancer.Methods: From January 2020 to June 2021,a total of 65 patients with advanced breast cancer who met the inclusion criteria and exclusion criteria in Inner Mongolia Forestry General Hospital were randomly divided into two groups.32 cases in the control group were given oral aromatase inhibitor letrozole tablets(2.5mg,once a day),exemestane(25mg,once a day)or anastrozole(1mg,once a day),and 30 cases in the experimental group were combined with capecitabine tablets(0.5g,three times a day)on this basis.The short-term efficacy(objective remission rate,disease control rate),adverse reactions and improvement of quality of life were observed and compared between the two groups.Results: There was no significant difference between the two groups in baseline characteristics such as age,expression of estrogen receptor and progesterone receptor,pathological type,distant metastasis and previous endocrine therapy(P>0.05).The objective remission rates of the two groups were 40% and 21.9% respectively,and the disease control rates were 86.7% and 43.8% respectively.The objective remission rate and disease control rate between the two groups were statistically significant(P<0.05).Most of the adverse reactions of the two groups were grade I/II.The experimental group included bone marrow suppression(23.3%),hand foot syndrome(30.0%),nausea/vomiting(26.7%),diarrhea(30.0%),fatigue(50.0%),and the control group included nausea/vomiting(3.1%),diarrhea(6.3%),fatigue(18.8%).The incidence of grade I/II adverse reactions between the two groups was statistically significant(P<0.05).A few grade Ⅲ/Ⅳ adverse reactions occurred,including myelosuppression(3.3%),hand-foot syndrome(3.3%),fatigue(6.71%),nausea/vomiting(3.3%)in the experimental group and fatigue(3.1%)in the control group.The incidence of grade Ⅲ/Ⅳ adverse reactions between the two groups was no statistically significant(P>0.05).The quality of life in experimental group and control group improved in 15 cases and 7 cases respectively,stabilized in 12 cases and 15 cases respectively,and decreased in 3 cases and 10 cases respectively.The effective rate of patients’ quality of life between the two groups was statistically significant(P<0.05).Conclusion: For hormone receptor positive/human epidermal growth factor receptor 2negative advanced breast cancer patients,compared with aromatase inhibitor,capecitabine metronome chemotherapy combined with aromatase inhibitor has better short-term curative effect,controllable adverse reactions,better tolerance,and is more conducive to improving the quality of life of patients.